MiNK Therapeutics opens randomized phase 2 Agent 797 study

MiNK Therapeutics (NASDAQ: INKT ) held its second-quarter earnings conference call on Thursday.

Below is the complete transcript from the call.

This transcript is brought to you APIs.

For real-time access to our entire catalog, please visit for a consultation.

The full earnings call is available at Summary MiNK Therapeutics moved Agent 797 into a randomized phase 2 study for acute lung injury and ARDS, with positive preliminary data showing improved patient outcomes.

The company initiated its first international named patient access program in Brazil, allowing physicians to request Agent 797 for patients with serious unmet needs.

Financials showed a narrowed net loss of $3.1 million, with cash and equivalents at $8.8 million, driven by operational investments in phase 2 study launch.

Strategic focus remains on advancing U.S. study sites, expanding clinical data, and maintaining financial discipline without expanding fixed infrastructure.

Management expressed confidence in Agent 797's potential and highlighted the drug's practicality and immune regulatory function as key strategic elements.

Full Transcript OPERATOR Good morning and welcome to MiNK Therapeutics Second Quarter 2026 Conference Call and webcast.

All participants will be in a listen-only mode until the question and answer session.

Please note this event is being recorded.

I would now like to turn the conference over to Stephanie Pernanakar from MiNK Therapeutics, MiNK Investor Relations.

Stephanie, please go ahead.

Stephanie Pernanakar, Investor Relations Thank you, operator, and thank you all for joining us today.

Today's call is being webcast and will be available on our website for replay.

I'd like to remind you that this call will include forward-looking statements including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities.

These statements are subject to risks and uncertainties.

Please refer to our SEC filings available on our website for a detailed description of these risks.

Joining me today are Dr.

Jennifer Buell, President and Chief Executive Officer, Dr.

Therese Hammond, Head of Development, and Melissa Boyol, Principal Financial Officer.

I'd like to turn the call over to Dr.

Buell to highlight our progress from this quarter.

Dr.

Buell.

Jennifer Buell, President and Chief Executive Officer Thank you, Stephanie.

Good morning and thank you for joining us.

The second quarter was an important period of execution for MiNK.

We moved Agent 797 into a randomized phase 2 study in patients with acute lung injury and ARDS.

We presented initial day 28 observations from treated patients and established our first international paid named patient access program.

Together these reflect the model we are building: rigorous clinical development, rapid delivery of an off-the-shelf cell therapy, and responsible access for patients with urgent unmet needs.

Critical illness is still treated largely by supporting failing organs while clinicians wait for the underlying injury to resolve.

Ventilators support the lungs, vasopressors support the circulation.

Antibiotics address infection.

There remained no approved pharmacologic therapy shown to reduce mortality in patients with ARDS or to restore coordinated immune function after severe lung injury.